Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Sodium hyaluronate injection.
- Who it may be relevant to
- Registry conditions: Platelets-rich Plasma, Osteoarthritis Knees Both, Meniscus Disorder, Cartilage Injury. Basic parameters: 20 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Therapeutic Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis and Periarticular Tissue Injury
Overview
To evaluate the safety and effectiveness of PRP injection therapy in the repair of osteoarthritis and periarticular soft tissue injury through a single-center, exploratory clinical study, and to provide a more reliable basis for the treatment of joint injury.
Interventions
- Drug Sodium hyaluronate injection
The control group was injected into the joint cavity with sodium hyaluronate injection..
Primary outcome measures
- X-ray [Time frame: pre-operation,3 weeks after treatment, 6 months after treatment]
- CT [Time frame: pre-operation,3 weeks after treatment, 6 months after treatment]
- MRI [Time frame: pre-operation,3 weeks after treatment, 6 months after treatment]
Eligibility criteria
Inclusion criteria
- The age range of the participants was 20 to 60 years old. Through a comprehensive clinical and imaging examination, it was conclusively determined that the individuals had knee osteoarthritis or experienced injuries to the cart, and meniscus surrounding the knee joint.
- The preoperative routine tests and examinations revealed no contraindications.
- Revised sentence: "Informed consent of the patient
Exclusion criteria
- The platelet count or function exhibits significant abnormalities、Systemic infection transmitted through the bloodstream.
- Prolonged usage of anti-inflammatory drugs and systemic corticoid administration.
- In injection site or damage to the skin.
- Patients with tumors or undergoing radiotherapy and chemotherapy.
- Pregnant or breastfeeding women.
- Individuals with mental illnesses who are unable to cooperate with follow-up procedures.
- Contraindications for MRI、Patients or their families do consent to participate in the study.
- Other circumstances that render participation in the study unsuitable.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Xijing Hospital — Xi'an
Publications
- Ramos-Gonzalez G, Salazar L, Wittig O, Diaz-Solano D, Cardier JE. The effects of mesenchymal stromal cells and platelet-rich plasma treatments on cutaneous wound healing. Arch Dermatol Res. 2023 May;315(4):815-823. doi: 10.1007/s00403-022-02451-y. Epub 2022 Nov 3. PMID 36326886
- Zhang Y, Xing F, Luo R, Duan X. Platelet-Rich Plasma for Bone Fracture Treatment: A Systematic Review of Current Evidence in Preclinical and Clinical Studies. Front Med (Lausanne). 2021 Aug 3;8:676033. doi: 10.3389/fmed.2021.676033. eCollection 2021. PMID 34414200
Identifiers
NCT: NCT06082531 · KY20232210